Ocular Therapeutix(OCUL) - 2023 Q4 - Annual Results

Exhibit 99.1 Ocular Therapeutix™ Reports Fourth Quarter and Full Year 2023 Results Leadership Appointments Move Ocular Towards Being a Leader in Retinal Care Screening Underway in AXPAXLI™ Phase 3 SOL-1 Trial for Wet AMD Dr. Dugel concluded, "I believe the Company has made outstanding progress over the last several months, with the initiation of the Phase 3 SOL-1 study with AXPAXLI in wet AMD and successful financings that raised more than $440 million in gross proceeds from existing and new top tier health ...